Selonsertib/Simtuzumab

N/A

Report date: 2022/01/14 13:23:58

Base Information

Drug NameSelonsertib/Simtuzumab

Drug Alias NameN/A

ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Monoclonal antibody humanized

Mechanisms of ActionApoptosis signal-regulating kinase 1 inhibitorsLysyl oxidase homolog 2 inhibitors

TargetsApoptosis signal-regulating kinase 1Lysyl oxidase homolog 2

Therapy Area/IndicationsMetabolic Dysfunction-Associated Steatotic Liver Disease

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryN/A

Global Highest StatusDiscontinued (Phase 2 Clinical)

Highest Status in ChinaN/A

Originator CompaniesGilead Inc

China Registration ClassN/A

Active CompaniesN/A

Active IndicationsN/A

Inactive IndicationsMetabolic Dysfunction-Associated Steatotic Liver Disease

ATC CodeN/A